MX2021010075A - Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. - Google Patents

Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.

Info

Publication number
MX2021010075A
MX2021010075A MX2021010075A MX2021010075A MX2021010075A MX 2021010075 A MX2021010075 A MX 2021010075A MX 2021010075 A MX2021010075 A MX 2021010075A MX 2021010075 A MX2021010075 A MX 2021010075A MX 2021010075 A MX2021010075 A MX 2021010075A
Authority
MX
Mexico
Prior art keywords
rna polymerase
polymerase variants
transcriptional capping
transcriptional
capping
Prior art date
Application number
MX2021010075A
Other languages
English (en)
Inventor
Amy E Rabideau
Athanasios Dousis
Kanchana Ravichandran
Margaret Franklin
Kevin Smith
Michelle Lynn Hall
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MX2021010075A publication Critical patent/MX2021010075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona variantes de ARN polimerasa para una eficiencia de transcripción alta.
MX2021010075A 2019-02-20 2020-02-19 Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. MX2021010075A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962808182P 2019-02-20 2019-02-20
US201962832314P 2019-04-11 2019-04-11
US201962885928P 2019-08-13 2019-08-13
PCT/US2020/018779 WO2020172239A1 (en) 2019-02-20 2020-02-19 Rna polymerase variants for co-transcriptional capping

Publications (1)

Publication Number Publication Date
MX2021010075A true MX2021010075A (es) 2021-12-10

Family

ID=72143648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010075A MX2021010075A (es) 2019-02-20 2020-02-19 Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.

Country Status (10)

Country Link
US (2) US11485960B2 (es)
EP (1) EP3927821A4 (es)
JP (1) JP2022521094A (es)
KR (1) KR20210142636A (es)
CN (1) CN113795579A (es)
AU (1) AU2020224103A1 (es)
CA (1) CA3130888A1 (es)
MA (1) MA55037A (es)
MX (1) MX2021010075A (es)
WO (1) WO2020172239A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
HUE059127T2 (hu) 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
US11202793B2 (en) 2016-09-14 2021-12-21 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
MA49922A (fr) 2017-08-18 2021-06-02 Modernatx Inc Procédés pour analyse par clhp
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. HIV RNA VACCINE
CN112921014B (zh) * 2019-12-05 2023-01-06 左炽健 T7RNA聚合酶突变体、mRNA、基因、表达载体及细胞
GB202307565D0 (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
JP2023549592A (ja) * 2020-10-20 2023-11-28 エスティー ファーム カンパニー リミテッド ５’－キャッピングされたｒｎａ合成用オリゴヌクレオチド
JP2024506629A (ja) * 2021-02-09 2024-02-14 バージニア コモンウェルス ユニバーシティー ｍｉｎｉ環状ＲＮＡ治療薬及びワクチン、並びにそれらの使用方法
TW202304944A (zh) * 2021-03-31 2023-02-01 美商現代公司 用於產生ｍＲＮＡ之三核苷酸及四核苷酸帽的合成
US20240229109A1 (en) 2021-04-01 2024-07-11 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
JP2024514182A (ja) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
WO2022221440A1 (en) 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
US20240218353A1 (en) 2021-06-17 2024-07-04 Modernatx, Inc. Alternative rna purification strategies
WO2023018923A1 (en) 2021-08-13 2023-02-16 Modernatx, Inc. Multicolumn chromatography mrna purification
EP4426853A1 (en) 2021-11-01 2024-09-11 ModernaTX, Inc. Mass spectrometry of mrna
WO2023081311A1 (en) 2021-11-05 2023-05-11 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
WO2023201204A1 (en) 2022-04-11 2023-10-19 Modernatx, Inc. Detection of mrna purity in a mixture
WO2023201294A1 (en) * 2022-04-14 2023-10-19 Modernatx, Inc. Rna polymerase variants
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
WO2023225524A1 (en) 2022-05-17 2023-11-23 Modernatx, Inc. Preparation of highly concentrated mrna
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
WO2024026005A1 (en) 2022-07-28 2024-02-01 Modernatx, Inc. Methods of rna purification
WO2024131998A2 (zh) * 2023-03-01 2024-06-27 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体、其制备方法及其在rna合成中的应用
WO2024191860A2 (en) 2023-03-10 2024-09-19 Modernatx, Inc. Nucleic acid influenza vaccines and respiratory virus combination vaccines
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
GB202406294D0 (en) 2024-05-06 2024-06-19 Thermo Fisher Scientific Baltics Uab Methods and compositions for producing capped mRNA

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279669A1 (en) 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
FR2822164B1 (fr) 2001-03-19 2004-06-18 Centre Nat Rech Scient Polypeptides derives des arn polymerases, et leurs utilisations
SI3611266T1 (sl) 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
AU2007238624B2 (en) 2006-04-14 2012-05-31 Cellscript, Llc Kits and methods for generating 5' capped RNA
EP2185716B1 (en) * 2007-08-08 2013-01-16 Wayne M. Barnes Improved t7 expression system
JP2011521626A (ja) * 2008-05-02 2011-07-28 エピセンター テクノロジーズ コーポレーション Ｒｎａポリホスファターゼの組成物、キットおよびそれらの使用
US8551752B2 (en) * 2008-08-08 2013-10-08 Tosoh Corporation RNA polymerase mutant with improved functions
PT3210622T (pt) * 2009-08-21 2021-03-03 Univ Georgia Vacina recombinante contra o paramixovírus aviário e método de preparação e utilização da mesma
JP2011223982A (ja) 2010-03-30 2011-11-10 Tosoh Corp Ｔ７ｒｎａポリメラーゼ融合蛋白質
EP2377938A1 (en) 2010-04-16 2011-10-19 Eukarys Capping-prone RNA polymerase enzymes and their applications
US9193959B2 (en) * 2010-04-16 2015-11-24 Roche Diagnostics Operations, Inc. T7 RNA polymerase variants with enhanced thermostability
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2012138416A1 (en) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
AU2012255913A1 (en) 2011-05-17 2013-11-21 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
ES2752081T3 (es) * 2011-06-16 2020-04-02 Univ California Complejos génicos sintéticos
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
FR2981088B1 (fr) * 2011-10-06 2013-11-29 Biomerieux Sa Arn polymerases mutees
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
AU2012358384A1 (en) 2011-12-21 2014-07-31 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
CA2862377A1 (en) 2011-12-30 2013-07-04 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
US9045740B2 (en) 2012-02-24 2015-06-02 University Of Massachusetts Modified T7-related RNA polymerases and methods of use thereof
US20150368625A1 (en) * 2012-03-27 2015-12-24 Massachusetts Institute Of Technology Artificial sigma factors based on bisected t7 rna polymerase
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014067551A1 (en) * 2012-10-29 2014-05-08 Technische Universität Dortmund T7 rna polymerase variants and methods of using the same
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
EP2971033B8 (en) * 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2955375A1 (en) 2014-07-17 2016-01-21 Modernatx, Inc. Terminal modifications of polynucleotides
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
US11608513B2 (en) 2015-05-29 2023-03-21 CureVac SE Method for adding cap structures to RNA using immobilized enzymes
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031241A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Rna mapping/fingerprinting
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
HUE057613T2 (hu) 2015-09-17 2022-05-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
HUE064227T2 (hu) * 2015-09-21 2024-02-28 Trilink Biotechnologies Llc Módszer 5'-sapkával ellátott rns-ek szintetizálására
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
US10144942B2 (en) 2015-10-14 2018-12-04 Translate Bio, Inc. Modification of RNA-related enzymes for enhanced production
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
MX2018004916A (es) 2015-10-22 2019-07-04 Modernatx Inc Vacuna contra el virus de la influenza de amplio espectro.
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
JP2018531290A (ja) 2015-10-22 2018-10-25 モデルナティーエックス， インコーポレイテッド 性感染症ワクチン
WO2017070622A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory syncytial virus vaccine
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
HUE059127T2 (hu) 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
AU2016369612B2 (en) 2015-12-17 2023-06-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN116144626A (zh) 2016-01-13 2023-05-23 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
MY201498A (en) 2016-05-18 2024-02-27 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MA45050A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
CN106244608B (zh) * 2016-08-08 2019-10-25 中国科学技术大学 诱导的t7 rna聚合酶
US11202793B2 (en) 2016-09-14 2021-12-21 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP3529255A1 (en) 2016-10-19 2019-08-28 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
BR112019008369A2 (pt) 2016-10-26 2019-10-01 Modernatx Inc ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos
MA46643A (fr) 2016-10-26 2019-09-04 Modernatx Inc Méthodes et compositions pour le mappage d'arn
US10907165B2 (en) 2016-10-31 2021-02-02 Cornell University Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
US20200032274A1 (en) 2017-02-01 2020-01-30 Moderna TX, Inc. Polynucleotide secondary structure
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
US20200368162A1 (en) 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
FI3596041T3 (fi) 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
EP3645711A4 (en) * 2017-06-30 2021-04-21 Codexis, Inc. T7 RNA POLYMERASE VARIANTS
CN111417724A (zh) * 2017-06-30 2020-07-14 科德克希思公司 T7 rna聚合酶变体
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
MA49922A (fr) 2017-08-18 2021-06-02 Modernatx Inc Procédés pour analyse par clhp
JP7408098B2 (ja) * 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
MA50751A (fr) 2017-08-18 2020-06-24 Modernatx Inc Vaccins à base d'arnm efficaces
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
EP3713601A4 (en) 2017-11-21 2022-03-09 Modernatx, Inc. VACCINES AGAINST EPSTEIN-BARR VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP3813848A4 (en) 2018-06-27 2022-07-20 ModernaTX, Inc. EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
WO2020056370A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
US20220047518A1 (en) 2018-09-19 2022-02-17 Moderna TX, Inc. Peg lipids and uses thereof
US20220409536A1 (en) 2018-09-19 2022-12-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3118947A1 (en) 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
MX2021011031A (es) * 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. HIV RNA VACCINE
CA3142352A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
WO2021030533A1 (en) 2019-08-14 2021-02-18 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
CA3154082A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Human cytomegalovirus vaccine
JP2022548957A (ja) 2019-09-19 2022-11-22 モデルナティエックス インコーポレイテッド キャップガイド及びｒｎａマッピングのためのその使用方法

Also Published As

Publication number Publication date
EP3927821A1 (en) 2021-12-29
CA3130888A1 (en) 2020-08-27
EP3927821A4 (en) 2023-01-25
US20230104080A1 (en) 2023-04-06
JP2022521094A (ja) 2022-04-05
AU2020224103A1 (en) 2021-09-16
CN113795579A (zh) 2021-12-14
MA55037A (fr) 2021-12-29
US20210309976A1 (en) 2021-10-07
WO2020172239A1 (en) 2020-08-27
US11485960B2 (en) 2022-11-01
KR20210142636A (ko) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2021010075A (es) Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
PH12018501159A1 (en) Composition and methods for immunooncology
MX2019013993A (es) Amplificación de etiquetado extremo múltiple de ácidos nucleicos.
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12019502171A1 (en) Composition and methods for immunooncology
CR20140538A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modificación de la transcripción dirigida por arn
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
WO2017122098A9 (en) Immunopotentiator enhanced superantigen mediated cancer immunotherapy
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
WO2018101663A3 (ko) 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법
MX2019004005A (es) Metodos para mejorar el resabio de bebidas alcoholicas usando alulosa.
MY176584A (en) Gluconate repressor variant, microorganism containing the same producing l-lysine, and method for producing l-lysine
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).
MX2020006910A (es) Metodo de plegamiento de laminas de vidrio.
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX2016017019A (es) Metodo para la preparacion de 4-alcoxi-1,1,1-trifluorobut-3-en-2-o nas de 1,1,1 trifluoroacetona.
CA187846S (en) Inverter
WO2019012162A3 (en) GENOMIC EDITING METHOD IN HOST CELL